top of page


  1. Ostrom QT et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2009-2013. NeuroOncol (2016) 18 (suppl 5) v1-v75.

  2. McNeill KA. Epidemiology of Brain Tumors. NeurolClin, 34 (2016), pp. 981-998.

  3. Louis D.N, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016; 131:803–820.

  4. Reifenberger G et al. Advances in the molecular genetics of gliomas-implications for classification and therapy. Nat Rev ClinOncol. 2017 Jul;14(7):434-452.

  5. Butowski N. Epidemoilogy and diagnosis of brain tumors. Continuum (MinneapMinn). 2015 Apr;21(2 Neuro-oncology):301-13



  1. Rudà R et al. EANO guidelines for the diagnosis and treatment of ependymal tumors. Neuro-Oncology 2017; 20(4): 445-456.

  2. Venegas E, Blanco C, Martin T, et al. Guía práctica del manejo y tratamiento  de los craneofaringiomas y otras lesiones paraselares. Endocrinol Nutr. 2015;62(1):e1-e13

  3. De B et al. Long-term outcomes of adult medulloblastoma patients treated with radiotherapy. J Neurooncol. 2018 Jan;136(1):95-104

  4. Ferreri AJM. Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):565-577

  5. Bernstein KA et al. Chordomas and Chondrosarcomas. The role of Radiation Therapy. J Surg Oncol. 2016 Oct;114(5):564-569.

  6. Murphy E, Suh J. Radiotherapy for vestibular Schwannomas: a critical review. Int. J. Radiation Oncology Biol. Phys 2011; 79( 4) 985–997

  7. Loeffler J, Shih H. Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab 2011; 96(7):1992–2003.

  8. British Neuro-Oncology Society. Guidelines on the diagnosis and management of Adult PNETs, Sheffield, England: British Neuro-Oncology Society; 2011

  9. Derdeyn C, Zipfel G, Alburquerque F, et al. Management of Brain Arteriovenous Malformations. Stroke 2017;48: 200-224



  1. Louis D.N, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016; 131:803–820.

  2. Sepúlveda-Sánchez J.M, Muñoz Langa J, Arráez M.A, et al. SEOM clinical guideline of diagnosis and management of low gradeglioma (2017). ClinTranslOncol 2018; 20:3–15.

  3. Pignatti F, Van den Vent M, Currant D, et al. Prognostic factors for survival in adults patients with cerebral low-grade gliomas. J ClinOncol 2002; 20:2074-2086.

  4. Shaw E, Wang M, Coons S. W, et al. Randomized trial of radiation therapy plus procarbazine,lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: Initial results of RTOG 9802. J ClinOncol 2012; 30:3065-3070.

  5. Van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005; 366: 985–90.

  6. Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J ClinOncol 2002; 20:2267.

  7. Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J RadiatOncolBiolPhys 1996; 36:549.

  8. Baumert B, Hegi M, van den Bent, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.LancetOncol 2016, 17:1521-1532.

  9. Bucker J, Shaw E, Pugh S, et al. Radiation plus Procarbazine, CCNU,and Vincristine in Low-Grade Glioma. N Engl J Med 2016, 374:1344-55.

  10.  Fisher B, Hu C, PhD, Macdonald D, et al. Phase 2 Study of Temozolomide-Based Chemoradiation Therapy for High-Risk Low-Grade Gliomas: Preliminary Results of Radiation Therapy Oncology Group 0424. Int J Radiation OncolBiolPhys 2015, 91:497-504.

  11. Weller M, Van de Bent M, Tonn J, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglialgliomas. Lancet Oncol 2017, 18:315-329.

  12. Nahed B, Redjal N, Brat D, et al. Management of patients with recurrence of diffuse low gradeglioma. A systematic review and evidence-based clinical practice guideline. J Neurooncol 2015, 125:609-630.


  1. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J NeurolNeurosurgPsychiatry. 1957; 20:22–39

  2. Goldsmith et al. Postoperative irradiation for subtotally resected meningiomas. J Neurosurg. 1994 Feb;80(2):195-201.

  3. Paldor I, Awad M, Sufaro Y, et al. Review of controversias in management of non-benign meningioma. Journal of Clinical Neuroscience 2016; 31:37–46

  4. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539; J Neurosurg129:35–47, 2018


  6. Aghi MK et al. Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation.Neurosurgery. 2009 Jan; 64 (1):56-60

  7. Huge GB et al. Management of atypical and malignant meningiomas: role of high-dose, 3D-conformal radiation therapy.J Neurooncol. 2000 Jun; 48(2):151-60

  8. FogliataA et al. Intensity modulation with photons for benign intracranial tumours: a planning comparison of volumetric single arc, helical arc and fixed gantry techniques. RadiotherOncol. 2008 Dec; 89 (3):254-62.

  9. Inoue T et al. Early intervention using high-precision radiotherapy preserved visual function for five consecutive patients with optic nerve sheath meningioma. Int J ClinOncol. 2018; 23(5): 826–834.

  10. Goldbrunner R et al. EANO guidelines for the diagnosis and treatment of meningioma.Lancet Oncol. 2016 Sep;17(9):e383-91

  11. Day S, Halasz L. Radiation therapy for WHO grade I meningioma. Chin ClinOncol2017;6(Suppl 1):1-9.

  12. Condra KS et al. Benign meningiomas: primary treatment selection affects survival. Int J RadiatOncolBiol Phys. 1997 Sep 1;39 (2):427-36.

bottom of page